Medigen Biotechnology (3176) — Cash Flow Reinvestment Rate
Medigen Biotechnology (3176) has a Cash Flow Reinvestment Rate of 0.26x as of December 2024, reinvesting NT$41.15 Million (capex NT$9.09 Million plus investments NT$-32.06 Million) from operating cash flow of NT$156.75 Million. Explore reinvestment intensity of Medigen Biotechnology to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Medigen Biotechnology Cash Flow Reinvestment Rate (2003–2024)
Historical reinvestment intensity for Medigen Biotechnology across 5 annual periods. Also explore balance sheet size of Medigen Biotechnology for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Medigen Biotechnology (2003–2024)
Year-by-year capital reinvestment analysis for Medigen Biotechnology. For live market cap and broader valuation context, see Medigen Biotechnology (3176) total market value.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 26.90x | NT$1.02 Billion | NT$37.92 Million | NT$58.68 Million | ▲ +1259.2% |
| 2021 | 1.98x | NT$1.02 Billion | NT$517.45 Million | NT$144.55 Million | ▼ -45.0% |
| 2015 | 3.60x | NT$1.06 Billion | NT$294.18 Million | NT$515.25 Million | ▲ +8952.2% |
| 2005 | 0.04x | NT$3.21 Million | NT$80.72 Million | NT$3.21 Million | ▲ +347.7% |
| 2003 | 0.01x | NT$3.96 Million | NT$445.46 Million | NT$3.96 Million | — |